Exherin

Exherin is a type of therapeutic agent that targets the cadherin family of proteins, which are involved in cell-cell adhesion. Exherin is primarily studied for its potential use in cancer therapy due to its ability to disrupt the adhesion of tumor cells, thereby inhibiting tumor growth and metastasis.

Mechanism of Action

Exherin works by binding to specific cadherins on the surface of tumor cells. Cadherins are a class of type-1 transmembrane proteins that play a crucial role in cell adhesion, ensuring that cells within tissues are bound together. By disrupting these interactions, Exherin can cause tumor cells to detach from each other, leading to reduced tumor growth and the prevention of metastasis.

Applications in Cancer Therapy

Exherin has shown promise in preclinical studies for the treatment of various types of cancer, including breast cancer, prostate cancer, and melanoma. By targeting cadherins, Exherin can potentially be used in combination with other therapeutic agents to enhance the overall efficacy of cancer treatment.

Research and Development

Research on Exherin is ongoing, with several studies focusing on its effectiveness and safety in animal models. Clinical trials are needed to determine its potential as a viable treatment option for human patients. The development of Exherin is part of a broader effort to create targeted therapies that can more effectively treat cancer with fewer side effects compared to traditional chemotherapy.

Related Pages

• Cadherin
• Cancer therapy
• Tumor
• Metastasis
• Breast cancer
• Prostate cancer
• Melanoma
• Chemotherapy

Resources

Latest articles - Exherin

• Most recent articles
• Ongoing trials

Source: Data courtesy of the U.S. National Library of Medicine. Since the data might have changed, please query MeSH on Exherin for any updates.

‎